These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 12552995)

  • 1. Comparison of CYFRA 21-1 and tissue polypeptide specific antigen (TPS) for detecting nasopharyngeal carcinoma.
    Tai CJ; Liu FY; Liang JA; Yang SN; Tsai MH; Kao CH
    Anticancer Res; 2002; 22(6B):3793-6. PubMed ID: 12552995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue polypeptide specific antigen (TPS) as a tumor marker in nasopharyngeal carcinoma.
    Sun SS; Hsieh JF; Tsai SC; Ho YJ; Kao CH
    Anticancer Res; 2000; 20(6C):4661-3. PubMed ID: 11205197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The value of CYFRA 21-1, a new tumor marker, in nasopharyngeal carcinoma.
    Lin WY; Yen TC; Cheng KY; Wang SJ
    Neoplasma; 1998; 45(1):21-4. PubMed ID: 9604997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early diagnosis and treatment monitoring roles of tumor markers Cyfra 21-1 and TPS in oral squamous cell carcinoma.
    Nagler RM; Barak M; Peled M; Ben-Aryeh H; Filatov M; Laufer D
    Cancer; 1999 Mar; 85(5):1018-25. PubMed ID: 10091783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beta-2-microglobulin (beta 2M) as a tumor marker in nasopharyngeal carcinoma.
    Lee JK; Tsai SC; Hsieh JF; Ho YJ; Sun SS; Kao CH
    Anticancer Res; 2000; 20(6C):4765-8. PubMed ID: 11205215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of CYFRA 21-1 and squamous cell carcinoma antigen in detecting nasopharyngeal carcinoma.
    Lee JK; Hsieh JF; Tsai SC; Ho YJ; Sun SS; Kao CH
    Ann Otol Rhinol Laryngol; 2001 Aug; 110(8):775-8. PubMed ID: 11510737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of CYFRA 21-1, TPS and CEA in different histologic types of non-small cell lung cancer.
    Nisman B; Amir G; Lafair J; Heching N; Lyass O; Peretz T; Barak V
    Anticancer Res; 1999; 19(4C):3549-52. PubMed ID: 10629651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early predicting recurrent cervical cancer with combination of tissue polypeptide specific antigen (TPS) and squamous cell carcinoma antigen (SCC).
    Hung YC; Shiau YC; Chang WC; Kao CH; Lin CC
    Neoplasma; 2002; 49(6):415-7. PubMed ID: 12584591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer.
    Tas F; Aydiner A; Topuz E; Yasasever V; Karadeniz A; Saip P
    J Exp Clin Cancer Res; 2000 Dec; 19(4):477-81. PubMed ID: 11277326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study of a new tumor marker, CYFRA 21-1, in squamous cell carcinoma of the cervix, and comparison with squamous cell carcinoma antigen.
    Tsai SC; Kao CH; Wang SJ
    Neoplasma; 1996; 43(1):27-9. PubMed ID: 8843956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen.
    Bonfrer JM; Gaarenstroom KN; Korse CM; Van Bunningen BN; Kenemans P
    Anticancer Res; 1997; 17(3C):2329-34. PubMed ID: 9245246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A comparison of serum Cyfra 21-1 and SCC AG in the diagnosis of squamous cell esophageal carcinoma].
    Ychou M; Khemissa-Akouz F; Kramar A; Senesse P; Grenier J
    Bull Cancer; 2001 Oct; 88(10):1023-7. PubMed ID: 11713038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of serum Cyfra 21-1 in patients with primary oral squamous cell carcinoma.
    Zhong LP; Zhu HG; Zhang CP; Chen WT; Zhang ZY
    Int J Oral Maxillofac Surg; 2007 Mar; 36(3):230-4. PubMed ID: 16965897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYFRA 21-1, TPA-M, TPS, SCC-Ag and CEA in patients with squamous cell lung cancer and in chemical industry workers as a reference group.
    Kulpa J; Wójcik E; Radkowski A; Kolodziejski L; Stasik Z
    Anticancer Res; 2000; 20(6D):5035-40. PubMed ID: 11326663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyfra 21-1 as a tumor marker for follow-up of patients with squamous cell carcinoma of the oropharynx.
    Alkotyfan K; Wiegand S; Müller HH; Windfuhr JP; Werner JA; Sesterhenn AM
    Anticancer Res; 2010 Jun; 30(6):2291-6. PubMed ID: 20651382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum tumor marker CYFRA 21-1 in the diagnostics of NSCLC lung cancer.
    Pavićević R; Milicić J; Bubanović G; Supe S
    Coll Antropol; 1998 Dec; 22(2):629-35. PubMed ID: 9887620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tissue polypeptide specific antigen (tps) and cytokeratin 19 fragment (CYFRA 21.1) immunoradiometric assay in non small cell lung cancer evaluation.
    Giovanella L; Ceriani L; Bandera M; Rimoldi R; Beghé B; Roncari G
    Q J Nucl Med; 1995 Dec; 39(4):285-9. PubMed ID: 8624791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of TPS in patients with head and neck malignancies: comparison with SCC.
    Molina R; Torres MD; Moragas M; Filella X; Jo J; Giménez N; Traserra J; Ballesta AM
    Anticancer Res; 1995; 15(2):479-84. PubMed ID: 7763026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring of therapy in inoperable lung cancer patients by measurement of CYFRA 21-1, TPA- TP CEA, and NSE.
    Ebert W; Hoppe M; Muley T; Drings P
    Anticancer Res; 1997; 17(4B):2875-8. PubMed ID: 9329552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective validation of serum CYFRA 21-1, beta-2-microglobulin, and ferritin levels as prognostic markers in patients with nonmetastatic nasopharyngeal carcinoma undergoing radiotherapy.
    Ma BB; Leungm SF; Hui EP; Mo F; Kwan WH; Zee B; Yuen J; Chan AT
    Cancer; 2004 Aug; 101(4):776-81. PubMed ID: 15305409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.